A newly discovered gene switch may help turn chemotherapy-resistant pancreatic cancer into a treatable disease.

A team from CNIO and CIEMAT eliminates cells that contain excessive copies of oncogenes using CRISPR gene editing. In cellular and animal models of neuroblastoma, small cell lung cancer and colon ...

Perioperative therapy has become a critical component in the management of resectable non–small cell lung cancer (NSCLC), particularly in the era of precision medicine. Although molecular testing is ...

Extrachromosomal DNAs (ecDNAs) are circular DNA structures located in the nuclei of cells outside chromosomes. They were originally discovered in chromosome spreads of cells obtained from embryonal ...

Pancreatic cancer is notoriously hard to treat, often resisting therapies that target its most common mutations. Researchers have now uncovered a hidden three-part loop that fuels tumor growth, ...

Enhancer hijacking emerges as a major “missing driver” mechanism in LBCL/PCN, enabling detection of non-chimeric oncogene activation such as IGL::BCL2, IGH::CCND2, and MAFA/MAFB rearrangements.

Please provide your email address to receive an email when new articles are posted on . Inhibiting RMB42 disrupted production of Myc proteins in pancreatic cancer cells. This approach could curtail ...

Cancer begins when mutations in specific genes override the body’s built-in controls on cell division, allowing rogue cells ...

The fireside chat session is scheduled for Wednesday, March 11, in Miami, Florida at 11:20 a.m. ET. A live and archived webcast of the session will be accessible under “Events & Presentations” in the ...